Through the Iran chaos, this one's been climbing 📈

*This email contains promotional content

Hey folks, Jeff Bishop here,

What a day yesterday!

Stocks absolutely ripped after President Trump announced a two-week ceasefire with Iran.

The Dow exploded 1,325 points higher, its best day since April 2025. The S&P 500 jumped 2.51%, the Nasdaq surged 2.80%, and crude oil cratered more than 16% as fears around the Strait of Hormuz eased. 

While it feels like the market may have found its footing, I’m seeing plenty of reports on social media that suggest the ceasefire is tottering… not to mention a final deal.

We could be looking at one big rug pull, and that’s why I’m focused on stocks that have been surging in spite of the conflict.

The stock at the top of my list has ripped more than 50% since its February low, and if you look at its chart, you would guess there never was an Iran conflict.

And its move may just be getting started.

👉 See Today's Tactical Trade Idea 👈

Here's why this one has my full attention:

This is a commercial-stage healthcare company that as of December 31 was sitting on roughly $12 million in cash with ZERO debt — nearly twice its current market cap. 

That means you could theoretically buy the whole company for less than the cash on its balance sheet.

And it gets better.

Just two days ago, this company announced a brand-new commercial agreement with Weill Cornell Medicine — one of the most prestigious medical institutions in the entire country…

The company’s AI-powered spine technology is being brought into a groundbreaking study at NewYork-Presbyterian/Weill Cornell, led by a nationally recognized triple-board certified specialist.

For a company with a market cap under $10 million, that kind of institutional validation is a massive credibility milestone.

👉 Get the Full Breakdown Here 👈

The company’s technology tackles a problem where the current "gold standard" procedure is invasive, painful, expensive, and has a success rate that's basically a coin flip. 

Its AI-powered solution is non-invasive, roughly half the cost, and published data shows it improves surgical outcomes by 10%.

This is exactly the kind of asymmetric setup I love to find: tiny market cap, real product, institutional validation, and a string of catalysts lined up over the next several months.

The stock already bounced over 50% off its February low, and with yesterday's market reversal adding fuel to small caps, I think this idea could be setting up for its next leg higher.

The stock is starting to make a big move.

Check out my full writeup as soon as possible.

To Your Success,

P.S. -⚡Daily Action in our Penny Stock Trading Room from 9am - 4pm ET  

(ALL are welcome)